Avalyn Pharma Inc. 8-K

What Happened

• Avalyn Pharma Inc. announced its financial results for the quarter ended March 31, 2026 and furnished a press release dated June 3, 2026 as Exhibit 99.1 to a Form 8‑K (Item 2.02). The Form 8‑K was signed by CEO Lyn Baranowski on June 3, 2026.
• The filing reports results of operations and financial condition for the quarter; the detailed figures and commentary are included in the press release furnished with the 8‑K.

Key Details

• Filing date: June 3, 2026 (Form 8‑K).
• Reporting item: Item 2.02 — Results of Operations and Financial Condition.
• Period covered: Quarter ended March 31, 2026.
• Exhibit: 99.1 — press release of Avalyn Pharma Inc. dated June 3, 2026; report signed by Lyn Baranowski (CEO).

Why It Matters

• This 8‑K signals Avalyn has released its latest quarterly results (earnings/quarterly results), which may contain metrics investors care about such as revenue, net income or loss, cash position and any business updates.
• Investors should read the furnished press release (Exhibit 99.1) and the company’s other SEC filings for the exact financial figures and management commentary to assess the company’s performance and outlook.